Cognitive Enhancers and Treatments for Alzheimer's Disease

Psychiatry: Third Edition

Volumn 2, Issue , 2008, Pages 2294-2317

  Yaari, Roy ^a   Tariot, Pierre N ^a,b   Schneider, Lon S ^c   Roose, Steven P ^d  

^a BANNER ALZHEIMER S INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Clinical trials; Memantine; Pharmacology; Treatment

Indexed keywords

EID: 77954137347     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470515167.ch107     Document Type: Chapter

References (236)

1. Adem A, Mohammed AK, and Winblad B (1990) Multiple effects of tetrahydroaminoacridine on the cholinergic system: Biochemical and behavioural aspects. Journal of Neural Transmission. Parkinsons Disease and Dementia Section 2, 113-128.
2. Aisen PS and Davis KL (1994) Inflammatory mechanisms in Alzheimer's disease: Implications for therapy. American Journal of Psychiatry 151. 1105-1113.
3. Aisen PS, Davis KL, Berg JD, et al. (2000) A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 54, 588-593.
4. Aisen PS, Schafer K, Grundman M, et al. (2002) Results of a multicenter trial of rofecoxib and naproxen in Alzheimer's disease. Neurobiology of Aging 23, S429.
5. Aisen PS, Saumier D, Briand R, et al. (2006) A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67(10), 1757-1763.
6. Antuono PG (1995) Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. Archives of Internal Medicine 155, 1766-1772.
7. Arendt T, Bigl V, Arendt A, et al. (1983) Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease. Acta Neuropathologica 61, 101-108.
8. Arendt T, Bigl V, Tennstedt A, et al. (1985) Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer's disease. Neuroscience 14, 1-14.
9. Arendt T, Bruckner MK, Lange M, et al. (1992) Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development-a study of molecular forms. Neurochemistry International 21 (3), 381-396.
10. Arterburn LM, Hall EB, and Oken H (2006) Distribution, interconversion, and dose response of n-3 fatty acids in humans. American Journal of Clinical Nutrition 83 (Suppl. 6), 1467S-1476S.
11. Asthana S, Baker LD, Craft S, et al. (2001) High-dose estradiol improves cognition for women with AD: Results of a randomized study. Neurology 57, 605-612.
12. Atack JR, Perry EK, Bonham JR, et al. (1986) Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. Journal of Neurochemistry 47, 263-277.
13. Bales KR, Tzavara ET, Wu S, et al. (2006) Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. Journal of Clinical Investigation 116(3), 825-832.
14. Barberger-Gateau P, Letenneur L, Deschamps V, et al. (2002) Fish, meat, and risk of dementia: Cohort study. British Medical Journal 325(7370), 932-933.
15. Bastianetto S, Ramassamy C, Dore S, et al. (2000) The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. European Journal of Neuroscience 12, 1882-1890.
16. Beher D, Clarke EE, Wrigley JD, et al. (2004) Selected non-steroidal antiinflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. Journal of Biological Chemistry 279(42), 43419-43426.
17. Bilikiewicz A and Gaus W (2004) Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. Journal of Alzheimer's Disease 6(1), 17-26.
18. Birks J (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews (1): CD005593.
19. Birks J and Flicker L (2003) Selegiline for Alzheimer's disease. The Cochrane Database of Systematic Reviews (1): CD000442.
20. Birks J, Grimley Evans J, Iakovidou V, et al. (2000) Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews (4): CD001191.
21. Bissette G and Myers B (1992) Somatostatin in Alzheimer's disease and depression. Life Sciences 51, 1389-1410.
22. Bondareff W, Mountjoy CQ, and Roth M (1982) Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Neurology 32, 164-168.
23. Bowen DM, Smith CB, White P, et al. (1976) Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99, 459-496.
24. Brodaty H, Corey-Bloom J, Potocnik FC, et al. (2005) Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 20 (2-3), 120-132.
25. Brookmeyer R, Gray S, and Kawas C (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. American Journal of Public Health 88, 1337-1342.
26. Brufani M and Filocamo L (1997) Rational design of new acetylcholin-ersterase inhibitors. In Alzheimer's Disease: From Molecular Biology to Therapy, Becker R (ed). Birkhauser, Boston, MA, USA, pp 171-177.
27. Bullock R, Touchon J, Bergman H, et al. (2005) Rivastigmine and donepe-zil treatment in moderate to moderately severe Alzheimer's disease over a 2-year period. Current Medical Research and Opinions 21(8), 1317-1327.
28. Burns A, Rossor M, Hecker J, et al. (1999) The effects of donepezil in Alzheimer's disease-results from a multinational trial. Dementia and Geriatric Cognitive Disorders 10, 237-244.
29. Buxbaum JD, Oishi M, Chen HI, et al. (1992) Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proceedings of the National Academy of Sciences of the United States of America 89, 10075-10078.
30. Caccamo A, Oddo S, Billings LM, et al. (2006) M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice. Neuron 49(5), 671-682.
31. Cherny RA, Atwood CS, Xilinas ME, et al. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676.
32. Christie JE, Shering A, Ferguson J, et al. (1981) Physostigmine and areco-line: Effects of intravenous infusions in Alzheimer presenile dementia. British Journal of Psychiatry 138, 46-50.
33. Chui HC, Victoroff JI, Margolin D, et al. (1992) Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 42, 473-480.
34. Corey-Bloom J, Anand R, Veach J, et al. (1998) A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate): A new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology 1, 55-65.
35. Cotman CW, Monaghan DT, and Ganong AH (1988) Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Annual Review of Neuroscience 11, 61-80.
36. Courtney C, Farrell D, Gray R, et al. (2004) Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised doubleblind trial. Lancet 363(9427), 2105-2115.
37. Davies P and Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer's disease (letter). Lancet 2, 1403.
38. Davis KL and Mohs RC (1982) Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. American Journal of Psychiatry 139, 1421-1424.
39. Davies P, Katzman R, and Terry RD (1980) Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer senile dementia. Nature 288, 279-280.
40. Davis KL, Thal LJ, Gamzu ER, et al. (1992) A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. New England Journal of Medicine 327, 1253-1259.
41. Dodel RC, Du Y, Depboylu C, et al. (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry 75(10), 1472-1474.
42. Dorman DC, Cote LM, and Buck WB (1992) Effects of an extract of Gingko biloba on bromethalin-induced cerebral lipid peroxidation and edema in rats. American Journal of Veterinary Research 53, 138-142.
43. Dumont E, Petit E, Tarrade T, etal. (1992) UV-C irradiation-induced per-oxidative degradation of microsomal fatty acids and proteins: Protection by an extract of Ginkgo biloba (EGb 761). Free Radical Biology and Medicine 13, 197-203.
44. Dunbar G, Demazieres A, Monreal A, et al. (2006) Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers. Journal of Clinical Pharmacology 46(7), 715-726.
45. Dysken MW, Mendels J, LeWitt P, et al. (1992) Milacemide: A placebo-controlled study in senile dementia of the Alzheimer-type. Journal of the American Geriatrics Society 40, 503-506.
46. Dysken M, Kuskowski M, Love S, et al. (2002) Ondansetron in the treatment of cognitive decline in Alzheimer dementia. American Journal of Geriatric Psychiatry 10, 212-215.
47. Enz A and Floersheim P (1997) Cholinesterase inhibitors: An overview of their mechanisms of action. In Alzheimer's Disease: From Molecular Biology to Therapy, Becker R (ed). Birkhauser, Boston, MA, USA, pp 211-215.
48. Etienne P, Robitaille Y, Gauthier S, et al. (1986) Nucleus basalis neuronal loss and neuritic plaques in advanced Alzheimer's disease. Canadian Journal of Physiology and Pharmacology 64, 318-324.
49. Farlow M, Gracon SI, Hershey LA, et al. (1992) A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. Journal of the American Medical Association 268, 2523-2529.
50. Feldman H, Gauthier S, Hecker J, et al. (2001) A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57, 613-620.
51. Feldman HH, Ferris S, Winblad B, et al. (2007) Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: The InDDEx study. Lancet Neurology 6(6), 501-512.
52. Fillit H, Weinreb H, Cholst I, et al. (1986) Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 11, 337-345.
53. Fioravanti M and Flicker L (2001) Efficacy of Nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database of Systematic Reviews (4): CD003159.
54. Flicker L and Evans JG (2001) Piracetam for dementia or cognitive impairment. Cochrane Database of Systematic Reviews (2): CD001011.
55. Folstein MF, Folstein SE, and McHugh PR (1975) Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12, 189-198.
56. Fournier J, Gauthier T, Keane P, et al. (1992) Neurotrophic effects of SR57746A, a new non-peptide compound: In vitro studies. British Journal of Pharmacology 106, 120P.
57. Fournier J, Steinberg R, Gauthier T, et al. (1993) Protective effects of theSR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience 55, 629-641.
58. Francis PT, Palmer AM, Sims NR, et al. (1985) Neurochemical studies of early-onset alzheimer's disease. Possible influence on treatment. New England Journal of Medicine 313, 7-11.
59. Francis PT, Palmer AM, Snape M, et al. (1999) The cholinergic hypothesis of Alzheimer's disease: A review of progress. Journal of Neurology, Neurosurgery and Psychiatry 66, 137-147.
60. Fritze J and Walden J (1995) Clinical findings with nimodipine in dementia: Test of the calcium hypothesis. Journal of Neural Transmission 46 (Suppl.), 439-453.
61. Galasko D, Bennett D, Sano M, et al. (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders 11, S33-S39.
62. th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, PA, USA.
63. Gasparini L, Ongini E, Wilcock D, et al. (2005) Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimers disease. Brain Research Reviews 48, 400-408.
64. Gervais F, Chalifour R, Garceau D, et al. (2001) Glycosaminoglycan mimet-ics: A therapeutic approach to cerebral amyloid angiopathy. Amyloid 8 (Suppl. 1), 28-35.
65. Gilman S, Koller M, Black RS, et al. (2005) AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64(9), 1553-1562.
66. st Annual Meeting. San Diego, CA, USA p 137. 10.
67. Glasky AJ, Melchior CL, Pirzadeh B, et al. (1994) Effect of AIT-082, a purine analog, on working memory in normal and aged mice. Pharmacology, Biochemistry and Behavior 47(2), 325-329.
68. Gozes I and Spivak-Pohis I (2006) Neuro trophic effects of the peptide NAP: A novel neuroprotective drug candidate. Current Alzheimer Research 3 (3), 197-199.
69. Grigorev VV, Dranyi OA, and Bachurin SO (2003) Comparative study of action mechanisms of dimebon and memantine on AMPA-and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bulletin of Experimental Biology and Medicine 136(5), 474-477.
70. Grundman M, Capparelli E, Kim HT, et al. (2003) A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Sciences 73(5), 539-55.
71. Gutzmann H and Hadler D (1998) Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: Update on a 2-year double-blind multicentre study. Journal of Neural Transmission 54 (Suppl.), 301-310.
72. Haase J, Halama P, and Horr R (1996) Effectiveness of brief infusions with Ginkgo biloba special extract EGb 761 in dementia of the vascular and Alzheimer-type. Zeitschrift Fur Gerontologie Und Geriatrie 29, 302-309.
73. Hak AE, Pols HA, Stehouwer CD, et al. (2001) Markers of inflammation and cellular adhesion molecules in relation to insulin-resistance in nondiabetic elderly: The Rotterdam study. Journal of Clinical Endocrinology and Metabolism 86, 4398-4405.
74. Haroutunian V, Greig N, Pei XF, et al. (1997) Pharmacological modulation of Alzheimer's β-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Brain Research. Molecular Brain Research 46(1-2), 161-168.
75. Harvey AL (1995) The pharmacology of galanthamine and its analogues. Pharmacology and Therapeutics 68, 113-128.
76. Hashimoto M, Kazui H, Matsumoto K, et al. (2005) Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? American Journal of Psychiatry 162(4), 676-682.
77. Henderson VW, Paganini-Hill A, Miller BL, et al. (2000) Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial. Neurology 54, 295-301.
78. Hofferberth B (1994) The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. Human Psychopharmacology 9, 215-222.
79. Holmes C, Wilkinson D, Dean C, et al. (2004) The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 63(2), 214-219.
80. Homma A, Takeda M, Imai Y, et al. (2000) Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, pleacebo-controlled study in Japan. E2020 Study Group. Dementia and Geriatric Cognitive Disorders 11(6), 299-313.
81. Honjo H, Ogino Y, Naitoh K, et al. (1989) In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). Journal of Steroid Biochemistry 34, 521-525.
82. Howard RJ, Juszocak E, Ballard CG, et al. (2007) Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine 357(14), 1382-1392.
83. Huguet F, Drieu K, and Piriou A (1994) Decreased cerebral 5-HT1A receptors during ageing: Reversal by Ginkgo biloba extract (EGb 761). Journal of Pharmacy and Pharmacology 46, 316-318.
84. Inestrosa NC, Alvarez A, Perez CA, et al. (1996) Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 16, 881-891.
85. Ingvar M, Ambros-Ingerson J, Davis M, et al. (1997) Enhancement by an ampakine of memory encoding in humans. Experimental Neurology 146(2), 553-559.
86. Janus C, Pearson J, McLaurin J, et al. (2000) A[beta] peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
87. Jhee SS, Chappell AS, Zarotsky V, et al. (2006) Multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjects. Journal of Clinical Pharmacology 46(4), 424-432.
88. Jick H, Zornberg GL, Jick SS, et al. (2000) Statins and the risk of dementia. Lancet 356(9242), 1627-1631.
89. Jorm AF (1986) Effects of cholinergic enhancement therapies on memory function in Alzheimer's disease: A meta-analysis of the literature. Australian and New Zealand Journal of Psychiatry 20, 237-240.
90. Jorm AF, Korten AE, and Henderson AS (1987) The prevalence of dementia: A quantitative integration of the literature. Acta Psychiatrica Scan-dinavica 76, 465-479.
91. Kalmijn S, Launer LJ, Ott A, et al. (1997) Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Annals of Neurology 42(5), 776-782.
92. Kanowski S, Fischof P, and Hiersemenzel R (1988) Wirksamkeitsnachweis von Neotropika am Beispiel von Nimodipin-ein Beitrag zur entwicklung geeigneter klinischer Prufmodelle. Z Gerontopsychol Psychiatr 1, 35-44.
93. Kanowski S, Herrmann WM, Stephan K, et al. (1996) Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer-type or multi-infarct dementia. Pharmacopsychiatry 29, 47-56.
94. Kavirajan H and Schneider LN (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A metaanalysis of randomized controlled trials. Lancet Neurology 6(9), 782-792.
95. Kaufer DI, Cummings JL, and Christine D (1996) Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study. Journal of Geriatric Psychiatry and Neurology 9, 1-6.
96. Khachaturian ZS (1985) Diagnosis of Alzheimer's disease. Archives of Neurology 42, 1097-1105.
97. Kim AJ, Shi Y, Austin RC, et al. (2005) Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. Journal of Cell Science 118(Pt. 1), 89-99.
98. Knapp MJ, Knopman DS, Solomon PR, et al. (1994) A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. The Journal of the American Medical Association 271(13), 985-991.
99. Knoll J (1988) The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl. Mechanisms of Ageing and Development 46, 237-262.
100. Kristofikova Z, Benesova O, and Tejkalova H (1992) Changes of high-affinity choline uptake in the hippocampus of old rats after long term administration of two nootropic drugs (Tacrine and Ginkgo biloba extract). Dementia 3, 304-307.
101. Labie C, Canolle B, Chatelin S, et al. (2006) Effects of paliroden (SR57667B) and xaliproden on adult brain neurogenesis. Current Alzheimer Research 3(1), 35-36.
102. Lahiri DK, Farlow MR, Hintz N, et al. (2000) Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. Acta Neurologica Scandinavica 176 (Suppl.), 60-67.
103. Lahiri DK, Nall C, and Farlow MR (1992) The cholinergic agonist carba-chol reduces intracellular beta-amyloid precursor protein in PC 12 and C6 cells. Biochemistry International 28, 853-860.
104. Lane RM, Potkin SG, and Enz A (2006) Targeting acetylcholinesterase and butyrylcholinesterase in dementia. International Journal of Neuropsychopharmacology 9, 101-124.
105. Lauritzen L, Hansen HS, Jorgensen MH, et al. (2001) The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Progress in Lipid Research 40(1-2), 1-94.
106. Le Bars PL, Katz MM, Berman N, et al. (1997) A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. Journal of the American Medical Association 278, 1327-1332.
107. Leber P (2002) Criteria used by drug regulatory authorities. In Evidence-Based Dementia Practice, Qizilbash N, Schneider L, Chui H, et al. (eds). Blackwell Science, Oxford, UK, pp 376-387.
108. Leissring MA, Farris W, Chang AY, et al. (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093.
109. Lermontova NN, Lukoyanov NV, Serkova TP, et al. (2000) Dimebon improves learning in animals with experimental Alzheimer's disease. Bulletin of Experimental Biology and Medicine 129(6), 544-546.
110. Lermontova NN, Redkozubov AE, Shevtsova EF, et al. (2001) Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels. Bulletin of Experimental Biology and Medicine 132(5), 1079-1083.
111. López-Arrieta JM and Birks J (2002) Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database of Systematic Reviews, (3): CD000147.
112. Lowe D, De Vivo M, Tripodi C, et al. (2006) MEM 1003, A novel L-type CA2+ channel modulator, as a potential therapeutic for Alzheimer's disease. International Conference on Alzheimer's Disease and Related Disorders, Madrid, Spain. (Abstract P4-437).
113. Loy C and Schneider L (2006) Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database of Systematic Reviews (1): CD001747.
114. Lupien SJ, de Leon M, de Santi S, et al. (1998) Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nature Neuroscience 1, 69-73.
115. Lynch G, Kessler M, Rogers G, et al. (1996) Psychological effects of a drug that facilitates brain AMPA receptors. International Clinical Psychopharmacology 11(1), 13-19.
116. Maelicke A, Samochocki M, Jostock R, et al. (2001) Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biological Psychiatry 49, 279-288.
117. Mann DM, Yates PO, and Marcyniuk B (1984) A comparison of changes in the nucleus basalis and locus coeruleus in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry 47, 201-203.
118. Mark RJ, Ashford JW, Goodman Y, et al. (1995) Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2 +deregulation, and cytoskeletal pathology. Neurobiology of Aging 16(2), 187-198.
119. Matsuoka N, Yamazaki M, and Yamaguchi I (1995) Changes in brain somatostatin in memory deficient rats: Comparison with cholinergic markers. Neuroscience 66, 617-626.
120. Maurer K, Ihl R, Dierks T, et al. (1997) Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. Journal of Psychiatric Research 31, 645-655.
121. Mazurov A, Hauser T, and Miller CH (2006) Selective alpha7 nicotinic acetylcholine receptor ligands. Current Medicinal Chemistry 13(13), 1567-1584.
122. McKeith IG, Galasko D, Kosaka K, et al. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47, 1113-1124.
123. McKhann G, Drachman D, Folstein M, et al. (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
124. McLaurin J, Kierstead ME, Brown ME, et al. (2006) Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nature Medicine 12(7), 801-808.
125. McShane R, Areosa Sastre A, and Minakaran N (2006) Memantine for dementia. Cochrane Database Systematic Reviews (2): CD003154.
126. Milgram NW, Racine RJ, Nellis P, et al. (1990) Maintenance on L-deprenyl prolongs life in aged male rats. Life Sciences 47, 415-420.
127. Mirra SS, Heyman A, McKeel D, et al. (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
128. Mohs RC, Davis BM, Johns CA, et al. (1985) Oral physostigmine treatment of patients with Alzheimer's disease. American Journal of Psychiatry 142, 28-33.
129. Mohs RC, Knopman D, Petersen RC, et al. (1997) Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders 11, S13-S21.
130. Mohs RC, Doody RS, Morris JC, et al. (2001) 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57, 481-488.
131. Matsuoka N and Aigner TG (1997) FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel potential antidementia drug, improves visual recognition memory in rhesus monkeys: Comparison with physostigmine. Journal of Pharmacology and Experimental Therapeutics 280, 1201-1209.
132. Mudher A and Lovestone S (2002) Alzheimer's disease-do tauists and baptists finally shake hands? Trends in Neurosciences 25(1), 22-26.
133. Muller D, Mendla K, Farber SA, et al. (1997) Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sciences 60, 985-991.
134. Mulnard RA, Cotman CW, Kawas C, et al. (2000) Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study. Journal of American Medical Association 283, 1007-1015.
135. Muresanu DF, Rainer M, and Moessler H (2002) Improved global function and activities of daily living in patients with AD: A placebo-controlled clinical study with the neurotrophic agent Cerebrolysin. Journal of Neural Transmission 62 (Suppl.), 277-285.
136. Newhouse PA, Potter A, Kelton M, et al. (2001) Nicotinic treatment of Alzheimer's disease. Biological Psychiatry 49(3), 268-278.
137. Nicholson CD (1990) Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 101, 147-159.
138. Nicoll JA, Wilkinson D, Holmes C, et al. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nature Medicine 9(4), 448-452.
139. Nitsch RM, Slack BE, Wurtman RJ, et al. (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258, 304-307.
140. Nordberg A (2001) Nicotinic receptor abnormalities of Alzheimer's disease: Therapeutic implications. Biological Psychiatry 49(3), 200-210.
141. Ohkura T, Isse K, Akazawa K, et al. (1994) Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocrine Journal 41, 361-371.
142. Olin J, Schneider L, Novit A, et al. (2001) Hydergine for dementia. The Cochrane Database of Systematic Reviews (2): CD000359.
143. Ono K, Hasegawa K, Naiki H, et al. (2004) Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Journal of Neuroscience Research 75(6), 742-750.
144. Orgogozo JM (2006) Vaccination treatment of AD (abstract S5-04-04). Alzheimer's and Dementia 2, S94
145. Paganini-Hill A and Henderson VW (1994) Estrogen deficiency and risk of Alzheimer's disease in women. American Journal of Epidemiology 140, 256-261.
146. Panisset M, Gauthier S, Moessler H, et al. (2002) Cerebrolysin in Alzheimer's disease: A randomized, double-blind, placebo-controlled trial with a neu-rotrophic agent. Journal of Neural Transmission 109(7-8), 1089-1104.
147. Panula P, Rinne J, Kuokkanen K, et al. (1998) Neuronal histamine deficit in Alzheimer's disease. Neuroscience. 82(4), 993-997.
148. Parkinson Study Group (1993) Effects to tocopherol and deprenyl on the progression of disability in early Parkinson's disease. New England Journal of Medicine 328(3), 176-183.
149. Perras C, Shukla VK, Lessard C, et al. (2005) Cholinesterase inhibitors for Alzheimer's disease: A systematic review of randomized controlled trials. Health Technology Assessment: Hta/Nhs R&D Hta Programme 58, 1117.
150. Perry EK, Perry RH, Blessed G, et al. (1977) Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1, 189.
151. Perry EK, Tomlinson BE, Blessed G, et al. (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. British Medical Journal 2, 1457-1459.
152. Peskind ER, Potkin SG, Pomara N, et al. (2006) Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. American Journal of Geriatric Psychiatry 14(8), 704-715.
153. Petersen RC, Stevens JC, Ganguli M, et al. (2001) Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1133-1142.
154. Petersen RC, Thomas RG, Grundman M et al. (2005) Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine 352, 2379-2388.
155. Pietschmann A, Kuklinski B, and Otterstein A (1992) Protection from uv-light-induced oxidative stress by nutritional radical scavengers. Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete 47, 518-522.
156. Pomara N, Doraiswamy PM, Tun H, et al. (2002) Mifepristone (RU 486) for Alzheimer's disease. Neurology 58 (9), 1436.
157. Radebaugh TS, Buckholtz NS, and Khachaturian ZS (1996) Fisher symposium: Strategies for the prevention of Alzheimer disease-overview of research planning meeting III. Alzheimer Disease and Associated Disorders 10, 1-5.
158. Rammes G, Rupprecht R, Ferrari U, et al. (2001) The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neuroscience Letters 306(1-2), 81-84.
159. Raskind MA, Sadowsky CH, Sigmund WR, et al. (1997) Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease. Archives of Neurology 54, 836-840.
160. Raskind M, Peskind ER, Wessel T, et al. (2000) Galantamine in Alzheimer's disease-a 6-month, randomized, placebo-controlled trial with a 6-month extension. Neurology 54, 2261-2268.
161. Reisberg B, Doody R, Stoffler A, et al. (2003) Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine 348(14), 1333-1341.
162. Relkin N, Szabo P, Adamiak B, et al. (2005) Intravenous immunoglobulin (IVIg) treatment causes dose-dependent alterations in β-Amyloid (Aβ) levels and anti-Aβ antibody titers in plasma and cerebrospinal fluid (CSF) of Alzheimer's Disease (AD) patients. Neurology 64 (Suppl. 1), A144.
163. Risner ME, Saunders AM, Altman JF, et al. (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics Journal 6(4), 246-254.
164. Ritchie CW, Bush AI, Mackinnon A, et al. (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Archives of Neurology 60, 1685-1691.
165. Ritchie CW, Ames D, Clayton T, et al. (2004) Metaanalysis of randomized trials of the effectiveness and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. American Journal of Geriatric Psychiatry 12, 358-369.
166. Rockenstein E, Adame A, Mante M, et al. (2003) The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. Journal of Neural Transmission 110(11), 1313-1327.
167. Rockenstein E, Torrance M, Mante M, et al. (2006) Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. Journal of Neuroscience Research 83(7), 1252-1261.
168. Rockwood K, Beattie BL, Eastwood MR, et al. (1997) A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease. Canadian Journal of Neurological Sciences 24, 140-145.
169. Rockwood K, Mintzer J, Truyen L, et al. (2001) Effects of a flexible galan-tamine dose in Alzheimer's disease: A randomised, controlled trial. Journal of Neurology, Neurosurgery and Psychiatry 71, 589-595.
170. Rogers J, Kirby LC, Hempelman SR, et al. (1993) Clinical trial of indometh-acin in Alzheimer's disease. Neurology 43, 1609-1611.
171. Rogers SL, Doody RS, Mohs RC, et al. (1998a) Donepezil improves cognition and global function in Alzheimer's disease: A 15-week, double-blind, placebo-controlled study.Donepezil Study Group. Archives of Internal Medicine 158, 1021-1031.
172. Rogers SL, Farlow MR, Doody RS, et al. (1998b) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease.Donepezil Study Group. Neurology 50, 136-145.
173. Roman GC, Tatemichi TK, Erkinjuntti T, et al. (1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260.
174. Rosen WG, Terry RD, Fuld PA, et al. (1980) Pathological verification of ischemic score in differentiation of dementias. Annals of Neurology 7, 486-488.
175. Rosler M, Anand R, Cicin-Sain A, et al. (1999) Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. British Medical Journal 318, 633-638.
176. Ruehl WW, Entriken TL, Muggenburg BA, et al. (1997) Treatment with L-deprenyl prolongs life in elderly dogs. Life Sciences 61, 1037-1044.
177. Ruether E, Husmann R, Kinzler E, et al. (2001) A 28-week, double-blind, placebocontrolled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. [erratum appears in Int Clin Psychopharmacol 2001 Nov; 16(6): 372]. International Clinical Psychopharmacology 16(5), 253-263.
178. Salloway S, Ferris S, Kluger A et al. (2004) Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial. Neurology 63, 651-657.
179. Sano M, Ernesto C, Thomas RG, et al. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New England Journal of Medicine 336, 1216-1222.
180. Saxton J, McGonigle-Gibson KL, Swihart AA, et al. (1990) Assessment of the severely impaired patient: Description and validation of a new neuropsychological test battery. Psychological Assessment 2, 298-303.
181. Schettini G (1991) Brain somatostatin: Receptor-coupled transducting mechanisms and role in cognitive functions. Pharmacological Research 23(3), p 203-214.
182. Schneider L (2002) Rivastigmine. In Evidence-Based Dementia Practice, Qizilbash N, Schneider L, Chui H, et al. (eds). Blackwell Science, Oxford, UK, pp 499-509.
183. Schneider L and Tariot PN (1997) Cognitive Enhancers for Alzheimer's Disease. In Psychiatry, Tasman A, Kay J, and Lieberman JA (eds), Vol. 2. WB Saunders, Philadelphia, PA, USA, pp 1685-1701.
184. Schneider LS, Anand R, and Farlow M (1998) Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. International Journal of Geriatric Psychopharmacology 1, S26-S34.
185. Schneider LS, Olin JT, Doody RS, et al. (1997) Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders 11, S22-S32.
186. Schneider LS, DeKosky ST, Farlow MR, et al. (2005) A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Current Alzheimer Research 2 (5), 541-551.
187. Shumaker SA, Legault C, Rapp SR, et al. (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. Journal of the American Medical Association 289, 2651-2662.
188. Siemers E, Skinner M, Dean RA, et al. (2005) Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clinical Neuropharmacology 28(3), 126-132.
189. Siemers ER, Quinn JF, Kaye J, et al. (2006) Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66(4), 602-604.
190. Simons M, Schwärzler F, Lütjohann D, et al. (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Annals of Neurology 52(3), 346-350.
191. Simpkins JW, Singh M, and Bishop J (1994) The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiology of Aging 15 (Suppl. 2), S195-S197.
192. Sparks DL, Sabbagh MN, Connor DJ, et al. (2005) Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results. Archives of Neurology 62(5), 753-757.
193. Spencer CM and Noble S (1998) Rivastigmine: A review of its use in Alzheimer's disease. Drugs Aging 13, 391-411.
194. Spinnewyn B (1992) Ginkgo biloba extract (EGb 761) protects against delayed neuronal death in gerbil. In Effects of Ginkgo Biloba Extract (EGb 761) on the Central Nervous System, Christen Y, Costentin J, and Lacour M (eds). Elsevier, Paris, France, pp 113-118.
195. Stern Y, Sano M, and Mayeux R (1987) Effects of oral physostigmine in Alzheimer's disease. Annals of Neurology 22, 306-310.
196. Tariot P, Schneider L, and Coleman PD (1993a) Treatment of Alzheimer's disease: Glimmers of hope?Chemistry and Industry 20, 801-807.
197. Tariot P, Schneider L, Patel S, et al. (1993b) Alzheimer's disease and (-)deprenyl: Rationales and findings. In Inhibitors of Monoamine Oxidase B: Pharmacology and Clinical Use in Neurodegenerative Disorders, Szelenyi I (ed). Birkhauser Verlag, Basel, Switzerland, pp 301-317.
198. Tariot PN and Federoff HJ (2003) Current treatment for Alzheimer's disease and future prospects. Alzheimer Disease Associated Disorders 17 (Suppl 4), S105-S113.
199. Tariot PN, Solomon PR, Morris JC, et al. (2000) A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54, 2269-2276.
200. Tariot PN, Cummings JL, Katz IR, et al. (2001) A randomized, doubleblind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society 49(12), 1590-1599.
201. Tariot PN, Loy R, Ryan JM, et al. (2002) Mood stabilizers in Alzheimer's disease: Symptomatic and neuroprotective rationales. Advanced Drug Delivery Reviews 54(12), 1567-77.
202. Tariot PN, Farlow MR, Grossberg GT, et al. (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. Journal of the American Medical Association 291(3), 317-324.
203. Tateishi J (2000) Sub acute myelo-optico-neuropathy: Clioquinol intoxication in humans and animals. Neuropathology 20 (Suppl.), S20-S24.
204. Tatton W (1993) "Tropic-like" reduction of nerve cell death by deprenyl without monoamine oxidase inhibition. Neurol Forum 4, 3-10.
205. Taylor J (1985) The effects of chronic, oral Ginkgo biloba extract administration on neurotransmitter receptor binding in young and aged Fisher 344 rats. In Effects of Ginkgo Biloba Extract on Organic Cerebral Impairment, Agnoli A, Rapin J, Scapagnini V, et al. (eds). John Libbey Eurotext, London, UK, pp 31-34.
206. Thal LJ, Schwartz G, Sano M, et al. (1996) A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group. Neurology 47, 1389-1395.
207. Thal LJ, Carta A, Doody R, et al. (1997) Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Disease and Associated Disorders 11, 46-49.
208. Thal LJ, Grundman M, Berg J, et al. (2003) Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology 61 (11), 1498-1502.
209. Tokita K, Inoue T, Yamazaki S, et al. (2005) FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats. European Journal of Pharmacology 527 (1-3), 111-120.
210. Tollefson GD (1990) Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biological Psychiatry 27, 1133-1142.
211. Tuszynski MH (2002) Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurology 1 (1), 51-57.
212. Tuszynski MH, Thal L, Pay M, et al. (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nature Medicine 11(5), 551-555.
213. van Dyck CH, Tariot PN, Meyers B, et al. (2007) A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Disease and Associated Disorders 21(2), 136-143.
214. van Groen T and Kadish I (2005) Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. Brain Research Reviews 48(2005), 370-378.
215. Vernon MW and Sorkin EM (1991) Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs Aging 1, 17-35.
216. Walker LC, Ibegbu CC, Todd CW, et al. (2005) Emerging prospects for the disease-modifying treatment of Alzheimer's disease. Biochemical Pharmacology 69(7), 1001-1008.
217. Wallace JL, Muscara MN, de Nucci G, et al. (2004) Gastric tolerabil-ity and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen derivative, NCX-2216 [3-[4-(2-fluoro-alpha-methyl-[1, 1(-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester]. Journal of Pharmacology and Experimental Therapeutics 309, 626-633.
218. Watkins PB, Zimmerman HJ, Knapp MJ, et al. (1994) Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. Journal of the American Medical Association 271, 992-998.
219. Watson GS, Cholerton BA, Reger MA, et al. (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. American Journal of Geriatric Psychiatry 13(11), 950-958.
220. Weitbrecht WU and Jansen W (1986) Primary degenerative dementia: Therapy with Ginkgo biloba extract. Placebo-controlled double-blind and comparative study. Fortschritte Der Medizin 104, 199-202.
221. Weyer G, Babej-Dolle RM, Hadler D, et al. (1997) A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology 36(2), 73-82.
222. Whitehouse PJ, Price DL, Struble RG, et al. (1982) Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215, 1237-1239.
223. Wilcock GK, Lilienfeld S, and Gaens E (2000) Efficacy and safety of galan-tamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ: British Medical Association 321, 1445-1449.
224. Wilcock GK, Black SE, Haworth J, et al. (2006) Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Aβ42-lowering agent, in Alzheimer's disease (AD): Results of a 12-month phase 2 trial and 1-year follow-on study. Alzheimer's and Dementia 2 (3)(Suppl. 1), S81-S82.
225. Winblad B and Poritis N (1999) Memantine in severe dementia: Results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). International Journal of Geriatric Psychiatry 14, 135-146.
226. Winblad B, Bonura ML, Rossini BM, et al. (2001) Nicergoline in the treatment of mild-to-moderate Alzheimer's disease: A European multicentre trial. Clinical Drug Investigation 21, 621-632.
227. Winblab B, Kilander L, Eriksson S, et al. (2006) Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study, [see comment] [erratum appears in Lancet. 2006 Jan 17; 367(9527): 1980]. Lancet 367(9516), 1057-1065.
228. Winblad B, Cummings J, Andreasen N, et al. (2007) A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry 22(5), 456-467.
229. Witkin JM and Nelson DL (2004) Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacology and Therapeutics 103(1), 1-20.
230. Wolozin B, Kellman W, Ruosseau P, et al. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Archives of Neurology 57(10), 1439-1443.
231. Yamazaki M, Matsuoka N, Maeda N, et al. (1996) FK960 N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate ameliorates the memory deficits in rats through a novel mechanism of action. Journal of Pharmacology and Experimental Therapeutics 279, 1157-1173.
232. Yang F, Lim GP, Begum AN, et al. (2005) Curcumin inhibits formation of Aβ oligomers and fibrils and binds plaques and reduces amyloid in vivo. Journal of Biological Chemistry (7), 5892-5901.
233. Youdim MB, Amit T, Bar-Am O, et al. (2006) Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. Neurotoxicity Research 10(3-4), 181-192.
234. Zubenko GS and Moossy J (1988) Major depression in primary dementia. Clinical and neuropathologic correlates. Archives of Neurology 45, 1182-1186.
235. Zubenko GS, Moossy J, and Kopp U (1990) Neurochemical correlates of major depression in primary dementia. Archives of Neurology 47, 209-214.
236. Zweig RM, Ross CA, Hedreen JC, et al. (1988) The neuropathology of amin-ergic nuclei in Alzheimer's disease. Annals of Neurology 24, 233-242.